Ovarian

ROSELLA study opens to recruitment

Ovarian cancer is the second most common gynaecologic malignancy. Most patients are asymptomatic until advanced stages of the disease, and for women with distant invasive epithelial ovarian cancer, the five-year survival is approximately 30%. Despite initial therapy, [...]

ROSELLA study opens to recruitment2023-11-02T15:56:56+11:00

ANZGOG’s ‘On the Down Low’ recognised at the Australian Podcast Awards

ANZGOG's new podcast 'On the Down Low' won 'Best New Podcast' at the Australian Podcast Awards, which celebrate the nation’s best audio talent and creativity. The podcast features raw and inspiring stories from women with ovarian [...]

ANZGOG’s ‘On the Down Low’ recognised at the Australian Podcast Awards2023-10-18T12:02:20+11:00

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment

EMBRACE is a Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2. Dr Katrin Sjoquist, Medical Oncologist [...]

ANZGOG subgroup study of ovarian and breast cancer patients EMBRACE closes to recruitment2022-07-01T11:34:46+10:00
Go to Top